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Abstract 
During the early phase of drug discovery, it is becoming increasingly important to acquire the full 
physicochemical profile of molecules. For this purpose, there is a strong interest in developing efficient and 
cost-effective platforms for fast and reliable measurements of physicochemical properties. We have 
developed an automated physchem platform which ensures that consistent, comprehensive, and high-
quality physicochemical property measurements and derived property information for 100's of compounds 
per week are available alongside potency data at the right time to guide compound progression decisions. 
We discuss the routine assessments of biomimetic properties using high throughput automated high-
performance liquid chromatography (HPLC) platforms, with details of the methods and hardware employed, 
also with illustrations of the quality and impact of the data generated. 
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Introduction 
The use of biomimetic/physicochemical measurements, such as lipophilicity and protein/artificial 
membrane binding, to help rationalise the behaviour of experimental molecules in biological environments 
is an important facet of modern drug discovery [1,2]. Such measurements can be used not only as 
surrogates to model and predict behaviour, but also to estimate the quality of a given molecule and thus its 
chances of progression [2,3]; indeed, high clinical attrition rates have been attributed to sub-optimal 
physicochemical properties [4,5]. High quality, high throughput methods for biomimetic measurements are 
key elements of these approaches. The partitioning and distribution of drug molecules between bio-phases 
are fundamental to drug action [6], modelling and understanding these processes provides insight into 
Absorption, Distribution, Metabolism and Excretion, ADME [6], the key elements of Pharmacokinetics, the 
science of what the body does to a drug. The Partition and Distribution coefficients of drug molecules 
between 1-Octanol and aqueous buffers (OW) are well-established standards, and these biomimetic 
estimates of lipophilicity/hydrophobicity demonstrably influence ADME profiles and other outcomes. The 
negative impact of excessive lipophilicity on the chances of progression of experimental molecules has 
come under particular scrutiny over the past decade and changed practices in drug discovery are evident by 
recent improvements in the physicochemical quality of molecules [7]. Lipophilicity measurements (such as 
log10 [OW-Partition], log P or the distribution at a given pH, log DpH) are demonstrably unreliable for poorly 
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soluble compounds [8]. However, fast gradient reversed phase high pressure liquid chromatographic (HPLC) 
methodologies using C-18 columns provide an effective and reliable replacement [9], irrespective of 
solubility [10]. Analyses of data generated in this manner gave an improved resolution of ADME outcomes; 
together with enhanced log P/log D predictions that have enabled the construction of better structure-
based in silico predictive models. Other non-silica based polymeric stationary phases are being investigated 
to provide insight into non-polar environments and the potential for intramolecular hydrogen bonding [11]. 
The grafting of stationary phases other than C-18, onto HPLC columns, enables the high throughput 
assessment of additional pertinent ADME interactions [12], in particular the plasma proteins human serum 
albumin (HSA) and alpha-1-acid-glycoprotein (AGP), plus phosphatidylcholine, which acts as a surrogate 
immobilised artificial membrane (IAM). The availability of these various biomimetic columns within fully 
automated HPLC platforms enables the high throughput and cost-effective gathering of sets of pertinent 
and reliable data, which can provide valuable insight on the likely behaviours in biological systems. 
Progressing compounds with good physicochemical properties are fundamental to pharmaceutical 
companies’ aspirations for the objective assessment of the qualities of lead and candidate molecules [13]. 
An automated platform ensures that consistent, comprehensive, and high-quality physicochemical property 
measurements and derived property information are available at the right time to guide compound 
progression decisions. 
The role and impact of biomimetic methods 
High throughput workflow for HPLC based assays at GSK 
The physicochemical/biomimetic assays are bundled to provide kinetic solubility [8], lipophilicity and 
biomimetic binding data on the majority of project compounds during lead discovery and optimisation. The 
process for preparing sample plates which are “ready to run” on the HPLC systems is shown in Figure 1. At 
GSK all experimental compounds are routinely dissolved and stored at 10 mM in dimethyl sulphoxide 
(DMSO) solution, for ease of automated handling. 50 L samples of this stock are dispensed in 96 well 
master plates for the kinetic solubility assay, merged to give fully populated plates. 5L of the solutions in 
the master plates are dispensed into daughter plates; standards and blanks are added to these plates and 
all the samples are diluted using the appropriate solvents such as DMSO and iso-propanol/water 
(50/50 v/v) to produce daughter plates for the lipophilicity and biomimetic binding assays respectively. 
Each daughter plate has a unique barcode used to generate the plate map.  
To ensure production of data of high quality and integrity, system and assay suitability checks are 
embedded in the sample process and data analysis. Calibration data is monitored before and after running 
the samples. A set of “check” standards with known lipophilicity and biomimetic binding data are run 
during each sequence of samples and the data checked to ensure they meet the defined criteria. 
An in-house developed application (Figure 2) retrieves the relevant compound information from the 
barcodes and creates a “worklist” which is uploaded into the HPLC systems and used for running the 
samples. The application extracts the pertinent data from the raw data and places it into an Excel 
spreadsheet where further data analysis is conducted. The automatic extraction of data is based on a set of 
user-defined rules which interrogate the chromatograms and flags anomalous data, such as multiple peaks. 
This allows more robust and efficient data processing and analysis. 
The generation of such volume of data has enabled the building of high quality in-house predictive 
models (discussed later in this publication) which are used for quality control. Comparison of measured 
data with predicted data using these models is routinely performed to highlight any anomalous data. 
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Figure 1. The GSK high throughput physchem sample preparation workflow 
In addition to the kinetic solubility data, this process enables the generation of high-quality lipophilicity 
and biomimetic binding data for 100’s of compounds to be generated weekly. 
High-performance liquid chromatographic (HPLC) based assays 
Horváth et al was amongst the first who used HPLC data for hydrophobicity measurements of amino 
acids [14]. It has been well described that chromatographic retention is related to the compound’s dynamic 
distribution between the stationary and mobile phases and this is governed by a compound’s 
hydrophobicity [15-17]. Hence HPLC offers an excellent automated platform to determine distribution 
coefficients of biologically active compounds between aqueous mobile phases and various non-polar and 
biomimetic stationary phases through measurements of retention times. 
Chromatographic hydrophobicity index from fast gradient C-18 HPLC: setting new standards in 
lipophilicity/hydrophobicity determinations  
The lipophilicity values of virtually all new compounds at GSK is measured by reversed phase HPLC using 
a C-18 column (50 x 2 mm 3 µM Gemini NX C18, Phenomenex, UK), at each of pH 2, 7.4 and 10.5, using 
buffered fast gradient acetonitrile-water mobile phases. The retention-time derived chromatographic 
hydrophobicity index (CHI) values are derived directly from the gradient retention times by using a 
calibration line obtained for standard compounds [9]. Translation of CHI values into Chrom log D values at 
the given pH is achieved using empirically-derived Equation 1 [10]. There is a deliberate offset on the scale 
to differentiate the data from the traditional octanol-water measurements, but there is a high correlation 
between the two (for soluble compounds). Figure 3 indicates how the charge profile of each compound can 
be estimated based on the changes in logD across the 3 pH values. For neutral molecules, the 3 are the 
same (i.e. the partition coefficient, Chrom log P); additionally, the highest Distribution constant value (for 
non-zwitterionic compounds) is usually a reliable estimate of the Chrom log P of the molecule.  
Chrom log D = (0.0857)*CHI - 2.00 .  (1) 
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Figure 2. Use of the physchem application for data analysis  
 
 Charge characteristic 
Chrom log D 
at pH: 
Neutral Weak acid Strong acid Weak base Strong base 
2 = X = X >X <X = X 
7.4 X X X X X 
10.5 = X <X = X = X >X 
Figure 3. Patterns of changes in log DpH, at high or low pH, compared to the measured value, X, at pH 7.4, 
used to classify the strength of charged motifs in compounds. 
The influence and impact of these chromatographic measurements [1,10] reflect other observations on 
the crucial role of modulating lipophilicity in drug discovery [2,18], both through their impact in building 
rational understandings of both ADMET outcomes and chances of successful compound progression. 
Increasingly, appreciation of the impact of maximising lipophilic ligand efficiency is driving drug discovery 
thinking; this embodies the “Minimum lipophilicity principle” proposed by Hansch [19], who proposed that 
“compounds should be made as hydrophilic as possible without loss of efficacy” by subtracting lipophilicity 
from potency (usually expressed as ligand lipophilicity efficiency, LLE = pIC50 – log P) [20]. Furthermore, the 
principle of concurrently minimising lipophilicity and aromaticity [21] is represented by the property 
forecast index (PFI), the summation of aromatic ring count [22,23] and a lipophilicity measure. The 
measured PFI (Chrom Log D7.4 + #Ar) is an integral part of GSK candidate quality aspirations [13], based on 
analyses of marketed drugs and internal attrition; ideally an oral candidate should have PFI <6, fasted-state 
simulated intestinal fluid (FaSSIF) solubility > 100 g/ml and a predicted dose of < 100 mg.  
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Protein binding assay  
Chemically bonded HSA HPLC stationary phase with column dimension of 50 x 3 mm (Chiral 
Technologies, France) are used for measuring compounds’ binding to plasma proteins by applying linear 
gradient elution up to 30 % iso-propanol with 50 mM ammonium acetate buffer, pH 7.4  [24]. The gradient 
retention times are standardised using a calibration set of mixtures. The %HSA bound gives a reliable 
indication of the free fraction of the compound in plasma when compared to more complex 
pharmacokinetic methods. The %HSA is converted to the affinity constant, log KHSA, using Equation 2: 
log KHSA = log [HSA% / (101-HSA%)] (2) 
  
 
Figure 4. a) Levels of HSA binding by HPLC measurement, log KHSA plotted versus Chrom log D7.4 with charges 
highlighted (See Figure 3) and b) Box-whisker plot of log KHSA vs binned measured PFI for GSK compounds, 
wherein KHSA = [%HSA binding/(101-%HSA binding)] using the %binding values derived from chromatographic 
measurements.  
Analysis of data derived from the HSA measurements show a clear increase in HSA binding with 
increasing lipophilicity (Figure 4a); when separated by charge, the increased propensity for binding by acidic 
a) 
b) 
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compounds, over and above their lipophilicity, is evident. The impact of aromaticity on HSA binding is also 
clear, given higher binding as PFI increases (Figure 4b). 
Phospholipid binding assay  
The binding of compounds to the immobilised artificial membrane (IAM) [25] is measured using 
commercially available immobilised phosphatidylcholine (PC DD2 100 x 4.6mm 10 µM, Regis Analytical, 
West Lafayette, USA) HPLC columns [26]. Gradient retention times obtained by applying an acetonitrile 
gradient up to 85 % are converted to chromatographic hydrophobicity indices (CHIIAM) using a calibration 
set of compounds. The CHIIAM values are converted to the logarithmic retention factors using the following 
formula: log KIAM = 0.046*CHIIAM + 0.42. CHIIAM binding gives an indication of the compound’s likely binding 
to tissues and further insights are emerging [27], notably semi-quantitative indicators of the risk of 
phospholipidosis [28], a cytotoxicity outcome characterised by the breakdown of phospholipids [29], due to 
cationic amphiphilic drugs (CADs). The GSK model is based on the equation CAD likeness = CHIIAM + Delta 
CHI, whereby Delta CHI = (CHIpH10.5 –CHIpH7.4) as measured in the C-18 assays at the given pH values. 
Unsurprisingly, given the hydrophobic chains of the phosphatidylcholine, IAM binding is driven by 
lipophilicity, but, in contrast to acid-binding HSA, the net negative charge of the phosphates leads to 
enhanced binding of basic molecules (Figure 5). 
 
Figure 5. Levels of IAM binding by HPLC measurement (expressed as log KIAM = 0.046*CHIIAM + 0.42) versus 
Chrom log D7.4 with bases highlighted 
Drug efficiency, HPLC DEmax 
Drug efficiency (DE, Equation 3) is a concept based on measured pharmacokinetic parameters, designed 
to guide lead optimisation and developability assessment, which reflects the free plasma concentration at 
the site of action (expressed as the fraction of the dose) [30]. Measured DE data correlate with HPLC DEmax 
values (Equation 4), generated biomimetically [31], using a combination of HSA and IAM columns Figure 6. 
The empirically-derived model generated from the data [32] is based on the notion that the unbound 
concentration is influenced by both plasma protein binding (HSA data) and the volume of distribution, for 
which the HPLC IAM data provides an excellent surrogate for the contributory tissue binding [33]. 
Increasingly, these measurements are having an impact in decision making, through estimation of clinical 
dose [34], and are being generated prospectively with in silico models available at GSK. The influence of 
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HPLC DEmax data on the selection of compounds for progression is illustrated in Figure 7 for a GSK 
programme, where most compounds had similar potencies (pIC50 7 to 8) but a range of HPLC DEmax values. 
The candidates selected from this set have HPLC DEmax > 1 % and are in the same space as the profiled 
drugs. These HPLC measurements, pertinent to DEmax, are increasingly being gathered in programmes at 
GSK and are starting to influence thinking, design and decision making. 
BiophaseConc (µg/mL)
DRUG Eff %= x100
Dose (µg/g)
 (3) 
log HPLC DEmax = 2 – (0.23 * log KHSA + 0.43 * log KIAM -0.72) (4) 
Drug Efficiency max (DEmax) is the maximum in vivo drug efficiency that could theoretically be achieved 
assuming 100 % oral absorption, no clearance, free permeability, and no active transport. 
High Potency plus High Drug Efficiency = Lower Dose Lower dose leads to reduced off-target risks. This 
contributes to reduced attrition. 
 
 
Figure 6. The plot of log (in vivo DE) vs log (HPLC DEmax) values for the training set of known drugs 
An additional parameter, the drug efficiency index (DEI) [29], can be generated by the summation of 
pXC50 and log10 (HPLC DEmax); DEI gives an estimate of the likely effective activity at the site of action, i.e. 
potency corrected for the free concentration. 
Impact of measurements to enable, validate and improve predictive methods 
Data collected by the various biomimetic measurements has enabled the building of high quality in-
house predictive models of each descriptor (e.g. Figure 8 for Chrom log D7.4). Good practice exploits 
iterative prediction/measurement cycles to build confidence in each series under optimisation; this also 
enables refinement of models on an ad hoc local basis in the rare cases that the global model does not 
perform well for a given structural series. The next level is to use these predictions as part of multivariate 
and other predictive models of various DMPK parameters (including drug efficiency), which are 
demonstrably improved by the enhanced predictions of physicochemical descriptors. Together, the output 
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of these initiatives is enabling an aspiration to predict by first intent in the physicochemical design process 
with demonstrable impacts. 
 
 
Figure 7. Plot of potency vs log (HPLC DEmax) values for programme compounds (green) overlaid with the 
training set of known drugs blue, with the candidates are chosen for progression in red. 
 
 
Figure 8. Trellised plot of calculated vs measured Chrom log D7.4 for compounds in 6 distinct chemical series 
with lines of best fit and unity; the r
2
 values illustrate the quality of the predictions 
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Conclusions 
The extensive use of high throughput biomimetic measurements impacts on the drug discovery process 
in many ways. Chromatographic lipophilicity measurements are at the core of Medicinal Chemistry 
programmes and can be used to predict outcomes, design better compounds and as quality indicators. The 
complementary measurements from other stationary phases such as HSA and IAM are now routinely used; 
increasing awareness with demonstrations of their utility and predictive impact. This should give an 
enhanced influence to programme progression in the future. 
 
Acknowledgements: We gratefully acknowledge the contributions of many colleagues in the GSK Phys 
Chem group, present and, largely past, notably Klara Valko and Alan Hill, plus many colleagues in 
computational and medicinal chemistry for model development and access to data and examples. 
References 
[1] R.J. Young, Physical Properties in Drug Design, in: N.A. Meanwell (Ed.) Tactics in Contemporary Drug 
Design, Springer Berlin Heidelberg, Berlin, Heidelberg, 2014, pp. 1-68. 
[2] N.A. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a 
means of improving compound disposition and safety. Chemical Research in Toxicology 24 (2011) 
1420-1456. 
[3] M.P. Gleeson, P.D. Leeson, H.van der Waterbeemd, Chapter 1. Physicochemical Properties and 
Compound Quality, The Handbook of Medicinal Chemistry, The Royal Society of Chemistry2015, pp. 
1-31. 
[4] P.D. Leeson, B. Springthorpe. The influence of drug-like concepts on decision-making in medicinal 
chemistry. Nat Rev Drug Discov 6 (2007) 881-890. 
[5] P.D. Leeson, R.J. Young. Molecular Property Design: Does Everyone Get It? ACS Medicinal Chemistry 
Letters 6 (2015) 722-725. 
[6] M.P. Gleeson, A. Hersey, D. Montanari, J. Overington. Probing the links between in vitro potency, 
ADMET and physicochemical parameters. Nat Rev Drug Discov 10 (2011) 197-208. 
[7] R.J. Young, P.D. Leeson. Mapping the Efficiency and Physicochemical Trajectories of Successful 
Optimizations. Journal of Medicinal Chemistry in press (2018). 
[8] A.P. Hill, R.J. Young. Getting physical in drug discovery: a contemporary perspective on solubility 
and hydrophobicity. Drug Discov Today 15 (2010) 648-655. 
[9] K. Valko, C. Bevan, D. Reynolds. Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: 
A High-Throughput Alternative to log P/log D. Analytical Chemistry 69 (1997) 2022-2029. 
[10] R.J. Young, D.V. Green, C.N. Luscombe, A.P. Hill. Getting physical in drug discovery II: the impact of 
chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today 16 (2011) 822-
830. 
[11] G. Caron, M. Vallaro, G. Ermondi, G.H. Goetz, Y.A. Abramov, L. Philippe, M. Shalaeva. A Fast 
Chromatographic Method for Estimating Lipophilicity and Ionization in Nonpolar Membrane-Like 
Environment. Molecular Pharmaceutics 13 (2016) 1100-1110. 
[12] K.L. Valkó. Lipophilicity and biomimetic properties measured by HPLC to support drug discovery. 
Journal of Pharmaceutical and Biomedical Analysis 130 (2016) 35-54. 
[13] M.K. Bayliss, J. Butler, P.L. Feldman, D.V. Green, P.D. Leeson, M.R. Palovich, A.J. Taylor. Quality 
guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug Discov Today 21 (2016) 
1719-1727. 
[14] C. Horváth, W. Melander, I. Molnár. Solvophobic interactions in liquid chromatography with 
nonpolar stationary phases. Journal of Chromatography A 125 (1976) 129-156. 
ADMET & DMPK 6(2) (2018) 74-84 High throughput biomimetic measurements in drug discovery 
doi: 10.5599/admet.530 83 
[15] F. Lombardo, M.Y. Shalaeva, K.A. Tupper, F. Gao. ElogDoct:  A Tool for Lipophilicity Determination in 
Drug Discovery. 2. Basic and Neutral Compounds. Journal of Medicinal Chemistry 44 (2001) 2490-
2497. 
[16] A. Vailaya, C. Horváth. Solvophobic Theory and Normalized Free Energies of Nonpolar Substances in 
Reversed Phase Chromatography. The Journal of Physical Chemistry B 101 (1997) 5875-5888. 
[17] K. Valkó, L.R. Snyder, J.L. Glajch. Retention in reversed-phase liquid chromatography as a function 
of mobile-phase composition. Journal of Chromatography A 656 (1993) 501-520. 
[18] M.J. Waring. Lipophilicity in drug discovery. Expert Opin Drug Discov 5 (2010) 235-248. 
[19] C. Hansch, J.P. Bjorkroth, A. Leo. Hydrophobicity and central nervous system agents: on the 
principle of minimal hydrophobicity in drug design. Journal of Pharmaceutical Sciences 76 (1987) 
663-687. 
[20] A.L. Hopkins, G.M. Keseru, P.D. Leeson, D.C. Rees, C.H. Reynolds. The role of ligand efficiency 
metrics in drug discovery. Nat Rev Drug Discov 13 (2014) 105-121. 
[21] T.J. Ritchie, S.J. Macdonald. Physicochemical descriptors of aromatic character and their use in drug 
discovery. Journal of Medicinal Chemistry 57 (2014) 7206-7215. 
[22] T.J. Ritchie, S.J. Macdonald. The impact of aromatic ring count on compound developability--are too 
many aromatic rings a liability in drug design? Drug Discov Today 14 (2009) 1011-1020. 
[23] T.J. Ritchie, S.J. Macdonald, R.J. Young, S.D. Pickett. The impact of aromatic ring count on 
compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic 
ring types. Drug Discov Today 16 (2011) 164-171. 
[24] K. Valko, S. Nunhuck, C. Bevan, M.H. Abraham, D.P. Reynolds. Fast Gradient HPLC Method to 
Determine Compounds Binding to Human Serum Albumin. Relationships with Octanol/Water and 
Immobilized Artificial Membrane Lipophilicity. Journal of Pharmaceutical Sciences 92 (2003) 2236-
2248. 
[25] C. Pidgeon, S. Ong, H. Liu, X. Qiu, M. Pidgeon, A.H. Dantzig, J. Munroe, W.J. Hornback, J.S. Kasher. 
IAM chromatography: an in vitro screen for predicting drug membrane permeability. Journal of 
Medicinal Chemistry 38 (1995) 590-594. 
[26] K. Valko, C.M. Du, C.D. Bevan, D.P. Reynolds, M.H. Abraham. Rapid-gradient HPLC method for 
measuring drug interactions with immobilized artificial membrane: Comparison with other 
lipophilicity measures. Journal of Pharmaceutical Sciences 89 (2000) 1085-1096. 
[27] F. Tsopelas, T. Vallianatou, A. Tsantili-Kakoulidou. Advances in immobilized artificial membrane 
(IAM) chromatography for novel drug discovery. Expert Opinion on Drug Discovery 11 (2016) 473-
488. 
[28] J.-M. Alakoskela, P. Vitovič, P.K.J. Kinnunen. Screening for the Drug–Phospholipid Interaction: 
Correlation to Phospholipidosis. ChemMedChem 4 (2009) 1224-1251. 
[29] N. Anderson, J. Borlak. Drug-induced phospholipidosis. FEBS Letters 580 (2006) 5533-5540. 
[30] S. Braggio, D. Montanari, T. Rossi, E. Ratti. Drug efficiency: a new concept to guide lead 
optimization programs towards the selection of better clinical candidates. Expert Opinion on Drug 
Discovery 5 (2010) 609-618. 
[31] K.L. Valkó, S.B. Nunhuck, A.P. Hill. Estimating Unbound Volume of Distribution and Tissue Binding 
by In Vitro HPLC-Based Human Serum Albumin and Immobilised Artificial Membrane-Binding 
Measurements. Journal of Pharmaceutical Sciences 100 (2011) 849-862. 
[32] K. Valko, E. Chiarparin, S. Nunhuck, D. Montanari. In vitro measurement of drug efficiency index to 
aid early lead optimization. Journal of Pharmaceutical Sciences 101 (2012) 4155-4169. 
[33] K.L. Valko, S.P. Teague, C. Pidgeon. In vitro membrane binding and protein binding (IAM MB/PB 
technology) to estimate in vivo distribution: applications in early drug discovery. ADMET and DMPK 
5 (2017) 14-38. 
S. Bunnally and R.J. Young  ADMET & DMPK 6(2) (2018) 74-84 
84  
[34] S. Teague, K. Valko. How to identify and eliminate compounds with a risk of high clinical dose 
during the early phase of lead optimisation in drug discovery. European Journal of Pharmaceutical 






©2018 by the authors; licensee IAPC, Zagreb, Croatia. This article is an open-access article distributed under the terms and 
conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/)  
